-
Innovation Ranking
NewInnovation Ranking – KYORIN Holdings Inc
KYORIN Holdings Inc (Kyorin) is a holding company that controls, administers and supports its group companies that conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, development, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over the counter (OTC) drugs, diagnostics, reagents, intermediates, diagnostics, industrial chemicals and other products. The company markets its product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other...
-
Company Insights
Innovation and Patenting activity of KYORIN Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of KYORIN Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Pulmonary Sarcoidosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Sarcoidosis - Drugs In Development, 2023’, provides an overview of the Pulmonary Sarcoidosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sarcoidosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sarcoidosis - Drugs In Development, 2023’, provides an overview of the Sarcoidosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KPRA-218 in Rhinovirus Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KPRA-218 in Rhinovirus Infections Drug Details: KPRA-218 is under development for the treatment of rhinovirus...